Bioxcel therapeutics announces late-breaking abstract on preliminary findings from phase 2 investigator-sponsored trial of bxcl701 and keytruda® in metastatic pancreatic ductal adenocarcinoma (pdac) selected for presentation at 2024 asco annual meeting

Poster presentation scheduled for june 1, 2024, 1:30-4:30 pm ct /2:30-5:30 pm et trial being led by georgetown university's lombardi comprehensive cancer center new haven, conn., april 24, 2024 (globe newswire) -- bioxcel therapeutics, inc. (nasdaq: btai), a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience and immuno-oncology, today announced that a late-breaking abstract with preliminary findings from the phase 2 investigator-sponsored trial of bxcl701 in combination with keytruda® (pembrolizumab) in previously treated metastatic pancreatic ductal adenocarcinoma (pdac) has been selected for presentation in a poster session at the 2024 american society of clinical oncology (asco) annual meeting.
BTAI Ratings Summary
BTAI Quant Ranking